1 Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the

2 Comirnaty® COVID-19 vaccine in nursing home residents

Beatriz Sánchez-Sendra¹, Eliseo Albert², Joao Zulaica¹, Ignacio Torres², Estela
Giménez², Pilar Botija³, María José Beltrán⁴, Celia Rodado⁵, Ron Geller^{1†} and David

5 Navarro^{2,6†}

- ¹Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC,
- 7 46980, Valencia, Spain.
- ⁸ ²Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 9 Valencia, Spain.
- 10 ³Dirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa,
- 11 Hospital Clínico Universitario de Valencia, Valencia, Spain.
- 12 ⁴Dirección de Enfermería, Departamento de Salud Clínico-Malvarrosa, Hospital
- 13 *Clínico Universitario de Valencia, Valencia, Spain.*
- ⁵Comisión Departamental de control de Residencias. Departamento de Salud València
- 15 *Clínico Malvarrosa*.
- ⁶Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 17 Spain
- 18
- 19 *†*Both senior authors contributed equally to the current work.
- Correspondence: David Navarro, Microbiology Service, Hospital Clínico
 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
 david.navarro@uv.es.

3 **Running title:** Neutralizing Ab vs. SARS-CoV-2 variants

4 **ABSTRACT** (150 words)

Immunosenescence may impact the functionality and breadth of vaccine-elicited 5 6 humoral immune responses. The ability of sera to neutralize the SARS-CoV-2 spike 7 protein (S) from Beta, Gamma, Delta, and Epsilon variants of concern (VOCs) relative 8 to the ancestral Wuhan-Hu-1 strain was compared in Comirnaty® COVID-19-9 vaccinated elderly nursing home residents (n=30) or younger individuals (n=18) and 10 non-vaccinated individuals who recovered from severe COVID-19 (n=19). In all 11 groups, some participants lacked NtAb against one or more VOCs, mainly the Beta variant (15-20%). Serum NtAb titers were lowest against the Beta variant followed by 12 13 Gamma, Epsilon, and Delta variants. Fold change reduction in NtAb titers relative to 14 the ancestral strain was greatest for the Beta variant (6.7-18.8) followed by Gamma 15 (3.6-6.2), Epsilon (2.9-5.8), and Delta (3.5-4.3) variants, regardless of the study group considered. In summary, older age, frailty, and concurrence of co-morbidities had no 16 impact on the serum NtAb activity profile against SARS-CoV-2 VOCs. 17

18 Key words: SARS-CoV-2 variants; Neutralizing antibodies; Comirnaty® COVID-19
19 vaccine; Nursing home residents

20 **INTRODUCTION** (2365 word)

Coronaviruses encode a proof-reading mechanism to minimize sequence variation in the
long RNA genomes that may compromise their survival in nature [1]. Nevertheless,
generation of variants during coronavirus replication in humans unfailingly ensues [2].
Many SARS-CoV-2 variants have emerged since its appearance late in 2019, some of

which may pose a threat to pandemic control due to their relative resistance to 1 2 neutralizing activity of antibodies elicited following natural infection or vaccination 3 with the original SARS-CoV-2 isolate (Wuhan/Hu-1); these variants, termed variants of 4 concern (VOC), incorporate amino acid substitutions or deletions in critical locations within the virus Spike (S) protein [3]. The Comirnaty® mRNA COVID-19 vaccine 5 6 encodes the ancestral strain S protein in a pre-fusion conformation [4]. Several studies 7 have shown a decreased ability of serum antibodies elicited by this vaccine to neutralize a number of VOCs compared to the original strain, most notably Beta (B.1.351), 8 9 Gamma (P.1), and more recently Delta (B.1.617.2)[5-12]. Nevertheless, elderly people 10 with frailty and co-morbidities, who are at the highest risk to develop severe forms of 11 COVID-19, were either not included or underrepresented in these studies. Since immunosenescence may be detrimental to the functionality and breadth of vaccine-12 13 elicited humoral immune responses [13], profiling of cross-neutralizing activity against 14 VOCs of sera from fully vaccinated elderly people is of major public health interest. In the current work, we address this issue by comparing the neutralizing capacity of sera 15 from Comirnaty® COVID-19-vaccinated nursing home residents with that of sera from 16 younger and seemingly healthy vaccinated individuals and non-vaccinated individuals 17 who recovered from severe COVID-19. 18

19 MATERIAL AND METHODS

20 Study groups

In this observational retrospective study, three population groups were considered. Group 1 included 30 nursing home (NH) residents with frailty and one or more comorbidities (23 females), randomly selected from one NH affiliated to the Clínico-Malvarrosa Health Department, Valencia (Spain), aged a median of 90 years (range 64-100). Twenty-two were SARS-CoV-2 naïve, as judged by a lack of antibodies targeting

the SARS-CoV-2 nucleoprotein (N), and 8 had contracted COVID-19 requiring hospitalization prior to receiving the first dose of the Comirnaty® COVID-19 vaccine, as determined by positive RT-PCR results in nasopharyngeal specimens and the detection of SARS-CoV-2 N antibodies. In all cases, the variant Wuhan/D614G was involved, as determined by whole-genome sequencing (not shown). All participants in this group were vaccinated on the same day and the sera were drawn at a median of 35 days after the second vaccine dose.

Group 2 comprised 18 healthy individuals (14 females) aged a median of 47.5 years
(range, 26-62). No molecular or serological evidence of prior SARS-CoV-2 infection
was available from any of these participants, whose sera were drawn at a median of 15
days since the completion of the vaccination schedule (range, 13-18).

Group 3 included 19 individuals (7 females; median age, 63 years; range 40-80) who were infected with the Wuhan/D614G strain (determined by whole-genome sequencing; data not shown), required hospitalization either in clinical wards or intensive care units, and eventually recovered from severe COVID-19. Sera from these individuals were obtained at a median of 105 days (range, 12-147) after molecular diagnosis of SARS-CoV-2 infection.

Group 4 (control group) included 10 healthy unvaccinated individuals (median age 52
years; range, 35-60 years), with no evidence of prior SARS-CoV-2 infection.

20 The study was approved by INCLIVA Research Ethics Committee. Informed consent21 was obtained from all participants.

22 Generation of SARS-CoV-2 with variant spikes

We introduced mutations in a mammalian expression vector encoding a codonoptimized SARS-CoV-2 S sequence from the Wuhan reference strain [14]. First, the

1	D614G mutation was introduced by site-directed mutagenesis. Subsequently, additional
2	site-directed mutagenesis and/or the cloning of synthetic fragments harboring the
3	mutations (Gblocks, IDT) was performed to introduce all mutations using the
4	NEBuilder HiFi DNA assembly mix (NEB). For the Beta variant (PANGO Lineage:
5	B.1.351; mutations D80A, L241Del, L242Del, A243Del, E484K, N501Y, D614G, and
6	A701V), a synthetic fragment encoding mutations D80A, L241Del, L242Del, A243Del,
7	E484K, and N501Y was cloned, and the A701V mutation introduced by site-directed
8	mutagenesis. For the Gamma variant (PANGO Lineage: P1 or B.1.1.28.1; mutations
9	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I,
10	and V1176F), a synthetic fragment encoding mutations (L18F, T20N, P26S, D138Y,
11	R190S, K417T, E484K, and N501Y) was cloned, and additional mutations H655Y,
12	T1027I, and V1176F were inserted by site-directed mutagenesis. For the Delta variant
13	(PANGO lineage: B.1.617.2; mutations T19R, del157/158, L452R, T478K, D614G,
14	P681R, and D950N) mutations were introduced by site-directed mutagenesis. Finally,
15	for the Epsilon variant (PANGO lineages B.1.427/B.1.429; mutations S13I, W152C,
16	L452R, D614G), a synthetic fragment encoding mutations S13I, W152C, and L452R
17	was cloned. All plasmids were verified by Sanger sequencing.

18 Virus neutralization assay

The neutralization capacity of circulating antibodies (NtAb) against the SARS-CoV-2 S protein was assessed using a GFP-expressing vesicular stomatitis virus pseudotyped with different Spike variants as previously described [15], but using A549-ACE2-TMPRSS2 cells (InvivoGen catalog code a549-hace2tps). All tests were done in duplicate using 5-fold serum dilutions ranging from 1:20 to 1:62,500, with ~1,000 focus forming units per well. Following 16 hours of infection, the GFP signal in each well was quantified using a live-cell microscope (Incucyte S3, Sartorius). Background

fluorescence from uninfected wells was subtracted from all infected well, and the GFP 1 2 fluorescence in each antibody-treated dilution was standardized to the average 3 fluorescence observed in mock-treated wells. Any value resulting in a relative GFP 4 signal of <0.001 versus was assigned a value of 0.001 to eliminate negative values. Finally, the reciprocal antibody dilution resulting in 50% virus neutralization was 5 6 calculated using the drc package (version $3.0 \square 1$) in R via a three \square parameter 7 log logistic regression model (LL.3 model). For the Beta, Gamma, and Epsilon 8 variants, all assays for the same serum were performed simultaneously with the Wuhan 9 reference strain unless neutralization was repeated due to high variability. As the Delta 10 variant was performed subsequently, we retested each serum was against both Delta and 11 the Wuhan strains unless no neutralization of Wuhan was observed in the previous assays. Sera testing negative (undetectable) were arbitrarily ascribed a titer of 1/20. 12

13 Quantitation of SARS-CoV-2 receptor binding domain-reactive antibodies

14 Total antibodies (IgG and IgM) against the SARS-CoV-2 S protein receptor-binding domain (RBD) were measured by Roche Elecsys® electrochemiluminescence sandwich 15 16 immunoassays (Roche Diagnostics, Pleasanton, CA, USA). The limit of detection of the assay is 0.4 IU/ml and its quantification range is between 0.8 and 250 IU/ml. Plasma 17 specimens were further diluted (1/10) for antibody quantitation when appropriate. The 18 19 assay is calibrated with the first WHO International Standard and Reference Panel for 20 anti-SARS-CoV-2 antibody [16]. Cryopreserved plasma (-20 °C) specimens were 21 thawed and assayed in singlets. Plasma specimens were diluted (1/10) for antibody 22 quantitation when appropriate.

23 Statistical methods

6

Geometric mean titers (GMTs) are reported throughout the study. Comparison of GMTs and medians across groups was carried out by the Student's t-test or the Mann-whitney U-test, as appropriate. Correlations between variables of interest were calculated by the Spearman Rank test. Frequency comparison across groups was performed using Fisher's exact test. Two-sided exact P values were reported. A P value <0.05 was considered statistically significant. The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA).

8 **RESULTS**

9 Detection of SARS-CoV-2-RBD and neutralizing antibodies in participants and 10 controls

11 Antibodies targeting the SARS-CoV-2 RBD were detectable in all but one (belonging to 12 group 3) out of the 67 participants and in none of the controls. Antibody levels across 13 the study groups, shown in Figure 1, were found to differ significantly, with nursing 14 home residents displaying higher levels as compared to that in participants from the 15 other two study groups. Similarly, using a pseudotyped vesicular stomatitis virus system, NtAb against the ancestral strain were detected in all but one (belonging group 16 3) participants and in none of the controls. Measurable NtAb against the different 17 SARS-CoV-2 VOCs included in the study were found at variable frequencies depending 18 19 upon the study group and the virus variant considered (Table 1). In all groups, some 20 participants lacked NtAb against one or more VOCs, most notably the Beta variant (15-21 20%). As for vaccinated individuals (groups 1 and 2), no significant differences in the detection rate of NtAb for any SARS-CoV-2 VOCs were found ($P \ge 0.5$) (Table 1). 22

23 Antibody neutralizing titers against SARS-CoV-2 S variants across study groups

Overall, all VOCs were neutralized to a lesser extent than the ancestral strain (Figure 2). 1 2 Specifically, serum NtAb titers were lowest against the Beta variant followed by 3 Gamma, Epsilon, and Delta variants, although wide ranges were observed for all 4 variants. This pattern was shared by all study groups (Figure 3 and Table 2). Accordingly, fold change reduction in NtAb titers relative to the ancestral strain was 5 6 greatest for the Beta variant (6.7-18.8) followed by Gamma (3.6-6.2), Epsilon (2.9-5.8), 7 and Delta (3.5-4.3) variants. The decrease in NtAb titers for any of SARS-CoV-2 VOCs 8 was not significantly different across comparison groups (Supplementary Figure 1).

9 Correlation between SARS-CoV-2 neutralizing and anti-RBD antibodies

10 The degree of correlation between levels of SARS-CoV-2 antibodies neutralizing 11 SARS-CoV-2 VOCs and total anti-RBD antibodies across the different population 12 groups was examined next. Overall, the correlation between these two parameters was 13 best for the ancestral strain and slightly decreased for all VOCs (Supplementary Figure 14 1). Of interest, this pattern was similar for both the vaccinated participants from nursing 15 home residents and healthy controls (Supplementary Table 1).

16 **DISCUSSION**

Reduced neutralization of VOCs as compared to the ancestral Wuhan-Hu-1 strain has 17 been observed in sera from individuals that were fully vaccinated against SARS-CoV-2 18 19 or have recovered from infection by either the ancestral Wuhan or the Wuhan/D164G 20 SARS-CoV-2 strains [5-12,17-18]. This has been observed in both the full SARS-CoV-21 2 virus or pseudotyped virus systems and is most notable for the Beta variant. As for 22 recipients of the Comrinaty[®] COVID-19 vaccine, this observation has been mostly 23 made in vaccine clinical trials participants and seemingly healthy health workers [5-12]. 24 Here, using S-pseudotyped SARS-CoV-2 variants, we extend this finding to include

1 elderly nursing home residents, both in SARS-CoV-2 naïve participants and those 2 infected by the Wuhan/D614G variant prior to vaccination. In effect, one month after 3 the second vaccine dose, sera from fully vaccinated nursing home residents retained the 4 ability to neutralize VOCs in most cases, but did so to a lesser extent than the ancestral strain, especially in the case of the Beta variant. Importantly, reduction in NtAb activity 5 6 against VOCs in this population group was not significantly different from that seen in 7 healthy fully-vaccinated controls (in sera obtained a median of two weeks after 8 vaccination) and unvaccinated individuals who had recovered from severe COVID-19 9 diagnosed within a median time of 3 months. Leaving aside participants who remained 10 unvaccinated and naturally contracted the infection, which are not strictly comparable to 11 vaccinees, our data strongly support the idea that older age, frailty, and concurrence of co-morbidities in fully-vaccinated individuals had no impact on the serum NtAb activity 12 13 profile against VOCs, including Delta variant that currently dominates in many 14 countries. The reduction in NtAb activity for all VOCs relative to that observed for the Wuhan-Hu-1 reference strain (fold-change reduction in NtAb activity) was higher for 15 all VOCs compared to other studies, especially the Beta variant. For example, using a 16 pseudotyped virus system, Liu et al. [5-7] reported a 2.7- and 1.4-fold reduction in the 17 18 NtAb activity against Beta and Delta variants, respectively, for sera from participants in 19 the Comirnaty[®] COVID-19 vaccine the trial, who were seemingly comparable to our 20 healthy vaccinated controls (13.1 and 3.0 fold reduction, respectively). In turn, using 21 live virus isolates in microneutralization assays, Lustig and colleagues [11] found fold 22 change reduction in NtAb titers of 10.4, 2.3, and 2.1 against the Beta, Gamma, and 23 Delta variants compared with the ancestral virus in health care workers fully vaccinated 24 with the Comirnaty® COVID-19 vaccine. Comparison of fold change reduction figures across studies is not straightforward, due not only to differences between population 25

group characteristics, especially in terms of age, sex, comorbidities, and SARS-CoV-2 infection status prior to vaccination, but also to differences in the pseudotyped virus platforms, the chosen S sequences used to represent each variant or the use of live viruses. Despite these differences, a similar pattern of NtAb activity against VOCs can be derived from these studies as well as our current work, with the Beta variant being less efficiently neutralized than the ancestral strain, followed by the Gamma, Epsilon, and Delta variants.

8 Levels of total antibodies binding SARS-CoV-2 RBD as quantitated by the Roche 9 Elecsys® electrochemiluminescence sandwich immunoassays strongly correlate with 10 NtAb titers against the ancestral SARS-CoV-2 strain [19,20]. Here we extended this 11 observation to those against Beta, Gamma, Delta, and Epsilon variants, suggesting that 12 SARS-CoV-2 RBD antibody levels measured by this assay may be a reliable proxy for 13 serum NtAb activity against these VOCs, regardless of the vaccinated population group 14 considered.

The relatively small sample size could be considered a limitation of the current study. Also, a limitation inherent to the use of S-pseudotyped viruses is the inability to assess the impact of variations in other viral genes outside of the S protein that could affect sera neutralization.

In summary, herein we show that neutralizing activity of sera against SARS-CoV-2 variants carrying critical escape mutations in the S gene is decreased relative to the ancestral strain in both qualitative and quantitative terms in nursing home residents recently vaccinated with the Comirnaty® COVID-19 vaccine. Nevertheless, the fold reduction in NtAb activity in this population group was not different from that seen in vaccinated controls and recovered COVID-19 individuals who had not been vaccinated. Importantly, among VOCs, the Delta variant that is currently predominant worldwide

was best neutralized by sera from participants in all study groups. Nevertheless, the
degree to which reduced neutralization activity of the different VOCs, and especially
the Delta variant, impact infection and/or disease in vaccinated nursing home residents
translate into diminished effective protection is currently under investigation.

5 ACKNOWLEDGMENTS

6 We are grateful to all personnel who work at nursing home residences affiliated with the 7 Clínico-Malvarrosa Health Department and at Clinic University Hospital, in particular 8 to those at the Microbiology laboratory, for their commitment in the fight against 9 COVID-19. Ignacio Torres holds a Río Hortega Contract (CM20/00090) from the 10 Carlos III Health Institute. Eliseo Albert holds a Juan Rodés Contract (JR20/00011) 11 from the Carlos III Health Institute. Estela Giménez holds a Juan Rodés Contract 12 (JR18/00053) from the Carlos III Health Institute. Ron Geller holds a Ramon y Cajal 13 Fellowship from the Spanish Ministry of Economy and Competitiveness (RYC-2015-14 17517).

15 FINANCIAL SUPPORT

16 This research work was supported by a grant from the European Commission–17 NextGeneration EU.

18 CONFLICTS OF INTEREST

19 The authors declare no conflicts of interest.

20 AUTHOR CONTRIBUTIONS

BS-S, EA, JZ, IT, and EG: Methodology and data validation. PB, MJB, CR: in charge
of implementing public health policies to combat SARS-CoV-2 epidemic at nursing
home residences affiliated to the Clínico-Malvarrosa Health Department. RG and DN:

Conceptualization, supervision, writing the original draft. All authors reviewed the
 original draft.

3 REFERENCES

4 1. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking

5 exoribonuclease activity are susceptible to lethal mutagenesis: evidence for
6 proofreading and potential therapeutics. PLoS Pathog. 2013;9:e1003565.

- 7 2. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and
 8 replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155-170.
- 3. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2
 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27:1109-

11 1117.

- 4. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits
 human antibody and TH1 T cell responses. Nature. 2020;586:594-599.
- 14 5. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. N
- 15 Engl J Med. **2021**;384:1466-1468.
- 16 6. Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited Neutralization against New SARS-
- 17 CoV-2 Spike Variants. N Engl J Med. **2021**;385:472-474.
- 7. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other
 SARS-CoV-2 variants. Nature. 2021;596:273-275.
- 20 8. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion,
- E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med.
 2021;27:620-621.

1	9. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced
2	antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12:3991.
3	10. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2
4	B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220-4236.e13.
5	11. Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta
6	(B.1.617.2) and other variants of concern following Comirnaty (BNT162b2,
7	BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill.
8	2021 ;26:2100557.
9	12. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to
10	SARS-CoV-2 and circulating variants. Nature. 2021;592:616-622.
11	13. Jergović M, Coplen CP, Uhrlaub JL, Nikolich-Žugich J. Immune response to
12	COVID-19 in older adults. J Heart Lung Transplant. 2021:S1053-2498(21)02303-2.
13	14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry
14	Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
15	Inhibitor. Cell. 2020 ;181:271-280.e8.
16	15. Gozalbo-Rovira R, Gimenez E, Latorre V, et al. SARS-CoV-2 antibodies, serum
17	inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J
18	Clin Virol. 2020 ;131:104611.
19	16. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO International
20	Standard and Reference Panel for anti-SARS-CoV-2 antibody. WHO/BS/2020.2403,
21	December 10, 2020.
22	17. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by
23	SARS-CoV-2 spike protein variants. Elife. 2020;9:e61312.

13

• •

10

1	18. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses
2	against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-
3	19/BNT162b2 vaccination. Nat Med. 2021;27:1525-1529.
4	19. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-
5	2 antibodies: Analytical and clinical evaluation. J Clin Microbiol. 2021; 59:e03149-20.
6	20. Poljak M, Oštrbenk Valenčak A, Štamol T, Seme K. Head-to-head comparison of
7	two rapid high-throughput automated electrochemiluminescence immunoassays
8	targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor
9	binding domain. J Clin Virol. 2021;137:104784.
10	FIGURE LEGENDS

Figure 1. Whisker plots depicting initial anti-SARS-CoV-2 RBD total antibody levels, 11 Roche Elecsys® electrochemiluminescence 12 as measured by the sandwich 13 immunoassays (Roche Diagnostics, Pleasanton, CA, USA), in nursing home residents (Group 1), healthy individuals fully vaccinated with the Comirnaty® vaccine (Group 2) 14 and unvaccinated, COVID-19 recovered individuals that required hospitalization in 15 internal medicine or intensive care units (Group 3). P value for comparison across the 16 three groups is shown. 17

Figure 2. Neutralizing antibody titers against the SARS-CoV-2 ancestral strain
(Wuhan-Hu-1) and variants of concern Beta, Gamma, Delta and Epsilon in sera form
participants. P values for pairwise comparisons are shown.

Figure 3. Neutralizing antibody titers against the SARS-CoV-2 ancestral strain (Wuhan-Hu-1) and variants of concern Beta, Gamma, Delta and Epsilon across study groups: nursing home residents (Group 1), healthy individuals fully vaccinated with the

1	Comirnaty® vaccine (Group 2) and unvaccinated, COVID-19 recovered individuals that
2	required hospitalization in internal medicine or intensive care units (Group 3).
3	Figure 4. Overall correlation between neutralizing antibody titers and anti-SARS-CoV-
4	2 RBD total antibody levels, as measured by the Roche Elecsys®
5	electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Pleasanton,
6	CA, USA), according to the SARS-CoV-2 S-variant. Rho and P values are shown.
7	Supplementary Figure 1. Fold change reduction in neutralizing antibody titers against
8	SARS-CoV-2 variants of concern as compared to the ancestral strain as a function of
9	the study group considered: nursing home residents (Group 1), healthy individuals fully
10	vaccinated with the Comirnaty® vaccine (Group 2) and unvaccinated, COVID-19
11	recovered individuals that required hospitalization in internal medicine or intensive care

SARS-CoV-2 variant	Number of participants with detectable neutralizing antibodies /total participants (%) ^a			
	Group 1	Group 2	Group 3	
Ancestral (Wuhan-	30/30 (100)	18/18 (100)	18/19 (94.7)	
Hu-1)				
Beta	24/30 (80)	16/18 (88.9)	16/19 (84.2)	
Gamma	27/30 (90)	17/18 (94.4)	17/19 (89.5)	
Delta	28/30 (93.3)	18/18 (100)	17/19 (89.5)	
Epsilon	28/30 (93.3)	17/18 (94.4)	17/19 (89.5)	
^a Group 1, nursing home	e residents fully	vaccinated with	the	
Comirnaty® vaccine; C	Group 2, healthy	individuals full	y vaccinated	
with the Comirnaty® vaccine; Group 3, unvaccinated, COVID-19				
ecovered individuals that required hospitalization in internal				
medicine or intensive care units.				

Table 1. Detectable neutralizing antibodies against differentSARS-CoV-2 variants across study groups

Table 2. Serum Neutralizing antibody titers against SARS-CoV-2 variants						
across stud	ly groups					
SARS-	Parameter	Study groups ^a				
CoV-2 variant		Group 1	Group 2	Group 3		
Beta	GMT (SD) Mean fold	238 (4,510) 18.8 (109.1)	124 (316) 13.1 (6.9)	122 (999) 6.7 (84.9)		
	reduction of NtAb titer (CI 95%) ^b					
Gamma	GMT (SD)	722 (8,612)	256 (435)	225 (1607)		
	Mean fold change reduction of NtAb titer (CI 95%) ^b	6.2 (9.1)	6.3 (6.6)	3.6 (4.8)		
Delta	GMT (SD)	1,037 (67,237)	543 (1,138)	231 (1,162)		
	Mean fold change reduction of NtAb titer (CI 95%) ^b	4.3 (10.9)	3.0 (0.6)	3.5 (4.1)		
Epsilon	GMT (SD)	774 (6,778)	261 (324)	283 (1,869)		
	Mean fold change reduction of NtAb titer (CI 95%) ^b	5.8 (7.7)	6.2 (6.6)	2.9 (2.2)		
(Wuhan- Hu-1)	GMT (SD)	4,509 (48,923)	1,622 (2,259)	442 (2,083)		

CI, confidence interval; GMT, geometric mean titer; NtAb, neutralizing antibodies; SD, standard deviation.

^aGroup 1, nursing home residents fully vaccinated with the Comirnaty® vaccine; Group 2, healthy individuals fully vaccinated with the Comirnaty® vaccine; Group 3, unvaccinated, COVID-19 recovered individuals that required hospitalization in internal medicine or intensive care units. ^bRelative to the NtAb titer against WA1/2020.







SARS-CoV-2 variants

Group 1



SARS-CoV-2 variants

Group 2



SARS-CoV-2 variants

Group 3



SARS-CoV-2 variants

